Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin's Disease and Non-Hodgkin's Lymphom
作者:
Kim Margolin,
Frederick Aronson,
Mario Sznol,
Michael Atkins,
Nicolae Ciobanu,
Richard Fisher,
Geoffrey Weiss,
James Doroshow,
Michael Bar,
Michael Hawkins,
James Mier,
Elisabeth Paietta,
Ellen Gaynor,
David Boldt,
期刊:
Journal of Immunotherapy
(OVID Available online 1991)
卷期:
Volume 10,
issue 3
页码: 214-220
ISSN:1524-9557
年代: 1991
出版商: OVID
关键词: Interleukin-2;Lymphokine-activated killer cells;Hodgkin's disease;Non-Hodgkin's lymphoma
数据来源: OVID
摘要:
Summary: Interleukin-2 (IL-2) plus lymphokine-activated killer (LAK) cell therapy has antineoplastic activity in renal cancer and malignant melanoma. In order to explore the activity of this therapy in Hodgkin's disease and non- Hodgkin's lymphoma, the Extramural IL-2/LAK Working Group (ILWG) treated 27 patients on two protocols using high-dose IL-2 and autologous LAK cells. Two of 12 patients with Hodgkin's disease experienced partial responses lasting 6 and 12 weeks. No patient with non-Hodgkin's lymphoma responded (p=NS). The toxicities of therapy were similar to those reported by the ILWG from trials of IL-2/LAK in solid tumors, consisting of transient hemodynamic, cardiopulmonary, renal and hepatic dysfunction, skin rash, fever, and flu-like symptoms. In view of the low response rate and the brief duration of these responses, we do not recommend the regimens reported here for further investigation in Hodgkin's disease or non-Hodgkin's lymphomas
点击下载:
PDF
(616KB)
返 回